Seeking Alpha

A partial clinical hold on the Achondroplasia treatment BMN 111 may be to blame for weakness in...

A partial clinical hold on the Achondroplasia treatment BMN 111 may be to blame for weakness in shares of BioMarin (BMRN +0.1%) in AH trading Thursday evening following what otherwise looked like a solid Q2 report and a generally positive BMN 673 update.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|